Patent 7585491 was granted and assigned to IMMUNOMEDICS, INC. on September, 2009 by the United States Patent and Trademark Office.
The invention relates to therapeutic conjugates with improved ability to target various cancer cells containing a targeting moiety and a therapeutic moiety. The targeting and therapeutic moieties are linked via an acid cleavable linkage that increases therapeutic efficacy of the immunoconjugate.